Serono

Dr. Reddy's and Merck Serono collaborate on biosimilars

Wednesday, June 6, 2012 01:07 PM

Dr. Reddy's Laboratories, an integrated global pharmaceutical company, and Merck Serono, a division of Merck, have formed a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs).

More... »

Medivir appoints Juserius commercial executive vice president

Thursday, May 17, 2012 10:44 AM

Medivir, a Stockholm-based specialty pharmaceutical company focused on infectious diseases, has appointed Henric Juserius to head the company's commercial activities.

More... »

Merck announces Swiss efficiency program, closure of Geneva office

Wednesday, April 25, 2012 10:05 AM

Global pharmaceutical and chemical company Merck Serono has announced efficiency plans for its Swiss operations as part of its comprehensive transformation program—focused on addressing unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization.

More... »

Ablynx, Merck expand partnership

Wednesday, November 9, 2011 03:08 PM

Ablynx has further expanded its relationship with Merck Serono and entered into a third agreement to co-discover and co-develop Nanobodies against two targets in osteoarthritis. The companies will exploit the unique Nanobody features and will develop multi-specific products, which have extended half-lives.

More... »

Merck, Ono Pharmaceutical collaborate

Tuesday, October 4, 2011 01:33 PM

Merck Serono has signed two separate agreements with Ono Pharmaceutical, Osaka, Japan to strengthen its multiple sclerosis and cancer franchises.

More... »

Icon and Bristol-Myers Squibb build on strategic partnership, extending it to early-phase work

Monday, September 5, 2011 08:00 AM

Icon and Bristol-Myers Squibb (BMS) have inked a preferred-provider agreement for early-phase development. This constitutes the CRO’s second sizable agreement with BMS; in June 2010, the two formed a strategic partnership, with Icon focused on providing global support for the drug developer’s clinical development pipeline.

More... »

Icon acquires Firecrest Clinical, adding portal technology to boost site quality while reducing errors and costs

Monday, July 25, 2011 08:02 AM

As large pharmaceutical companies scrutinize the pack of mid- and top-tier CROs to determine who wins the coveted strategic-partnership agreements, there’s a mad scramble among CROs to differentiate themselves from one another and stand out as efficient, high quality, exciting and deserving.

More... »

EMD Serono names Hoyes president

Wednesday, July 20, 2011 11:33 AM

EMD Serono, an affiliate of Germany-based Merck, has named James Hoyes president. He will be responsible for driving the strategic direction of the U.S. commercial organization as well as managing the day-to-day business of the U.S. affiliate of Merck. Hoyes will also serve as a member of the executive management board for Merck Serono, the global pharmaceuticals division of Merck.

More... »

Merck Serono changes R&D organizational structure

Thursday, July 7, 2011 02:02 PM

Merck Serono, a division of Merck of Darmstadt, Germany, is putting a new organizational structure for research and development into effect. Two dedicated groups, focusing on different stages of pharmaceutical innovation (pre- and post- proof-of-concept), will be created as a first step in redesigning Merck Serono's R&D model.

More... »

MS research funding awards given

Wednesday, July 6, 2011 10:13 AM

Merck Serono and Fast Forward announced the second group of recipients to receive funding designed to speed research advances in high potential areas of multiple sclerosis (MS) research.

More... »